Clinical trials: Paclitaxel, completed
Gastric Cancer
Phase II Study of ABI-007 for Gastric Cancer
The purpose of this study is to evaluate the efficacy and safety of tri-weekly ABI-007 for recurrence or unresectable gastric cancer patients who have received one prior regimen containing fluoropyrimidine and developed disease…
- Trial name
- NCT00661167
- Testing
- ABI-007
- Where
- 10 sites in Japan
- Volunteers
- 56 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Breast Cancer
A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer
The purpose of this study is to determine the maximum tolerated dose (MTD) of GRN163L in combination with paclitaxel and bevacizumab in patients with locally recurrent or metastatic breast cancer (MBC)
- Trial name
- NCT00732056
- Testing
- GRN163L
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Geron Corporation
Breast Cancer
A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer
This single arm study will assess the efficacy and safety of sequential neoadjuvant chemotherapy and bevacizumab (Avastin), before surgery and/or radiotherapy, in participants with inflammatory or locally advanced operable breast…
- Trial name
- NCT00559845
- Testing
- 5-fluorouracil, Epidoxorubicin, Cyclophosphamide
- Where
- 8 sites in Italy
- Volunteers
- 56 people
- Sponsor
- Hoffmann-La Roche
Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer
Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.
Pancreatic ductal adenocarcinoma (PDAC) remains a dreadful disease due to its often advanced stage at diagnosis and poor sensitivity to chemotherapy.
- Trial name
- LAPTOP (NCT04247165)
- Testing
- Gemcitabine, Nab-paclitaxel, Nivolumab
- Where
- Denmark
- Volunteers
- 55 people
- Sponsor
- Herlev Hospital
Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer AJCC v7
Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
This randomized phase III trial compares how well two different combination chemotherapy regimens (doxorubicin hydrochloride, cisplatin, and paclitaxel versus carboplatin and paclitaxel) work in treating patients with endometrial…
- Conditions
- Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7
- Trial name
- NCT00063999
- Testing
- Carboplatin, Cisplatin, Doxorubicin Hydrochloride
- Where
- 650 sites in United States, Canada and 1 more
- Volunteers
- 1,381 people
- Sponsor
- GOG Foundation
Head and Neck Cancer
The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC
The BURAN study is a randomized, open-label phase III study to assess the treatment effect of once-daily buparlisib in combination with weekly paclitaxel compared to weekly paclitaxel alone in patients with refractory, recurrent…
- Trial name
- BURAN (NCT04338399)
- Testing
- Buparlisib & Paclitaxel
- Where
- 162 sites in United States, Argentina and 15 more
- Volunteers
- 487 people
- Sponsor
- Adlai Nortye Biopharma Co., Ltd.
Peripheral Arterial Disease
Paclitaxel Coated Balloon Catheter for Prevention of Restenosis in Femoropopliteal Arteries
The PACCOCATH FEM study is a randomized, double-blinded German multicenter trial on the efficacy and tolerance of a paclitaxel coated balloon catheter in prevention of restenosis after femoropopliteal angioplasty.
- Trial name
- PACCOCATH_F (NCT00472472)
- Testing
- paclitaxel coated balloon catheter (device with drug)
- Where
- 2 sites in Germany
- Volunteers
- 87 people
- Sponsor
- University Hospital, Saarland
Advanced/Metastatic Non-Small Cell Lung Cancer
A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer
The purpose of this study is to determine whether progression-free survival with ixabepilone is superior to that achieved with paclitaxel plus carboplatin in participants with advanced nonsmall-cell lung cancer and beta III…
- Trial name
- NCT00723957
- Testing
- Ixabepilone, 32 mg/m^2, Paclitaxel, 200 mg/m^2, Carboplatin (area under the concentration curve [AUC] 6)
- Where
- 33 sites in United States, Argentina and 8 more
- Volunteers
- 260 people
- Sponsor
- R-Pharm
Squamous Cell Carcinoma of the Head and Neck
Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer
This phase two trial will determine the tumor response rate at the primary site and at involved regional nodes to two cycles of an IC regimen of weekly Abraxane and cetuximab given in combination with cisplatin and 5-FU in…
- Trial name
- NCT00736944
- Testing
- Abraxane, Cetuximab, Cisplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Washington University School of Medicine
Coronary Artery Disease
TAXUS ATLAS: TAXUS Liberté™-SR Stent for the Treatment of de Novo Coronary Artery Lesions
TAXUS ATLAS is a global, multi-center, single-arm, non-inferiority trial comparing results from patients treated with the TAXUS Liberté stent to an historical TAXUS Express control.
- Trial name
- NCT00371709
- Testing
- TAXUS Liberté-SR, TAXUS™ Express
- Where
- 62 sites in United States, Australia and 5 more
- Volunteers
- 871 people
- Sponsor
- Boston Scientific Corporation
Pancreatic Adenocarcinoma Metastatic
Scheduling Nab-paclitaxel With Gemcitabine
Metastatic pancreatic cancer is difficult to treat. Until recently, most patients would be offered treatment with a chemotherapy drug called gemcitabine.
- Trial name
- SIEGE (NCT03529175)
- Testing
- Abraxane (nab-paclitaxel), Gemcitabine
- Where
- 23 sites in United Kingdom
- Volunteers
- 146 people
- Sponsor
- CCTU- Cancer Theme
Catheter Related Complications
Central Catheters Used for Chemotherapy in Women With Breast Cancer
The overall aim of this study is to evaluate two different central venous lines, PICC-lines (PICC) and subcutaneous venous access ports (SVAP) used for chemotherapy in women with breast cancer.
- Trial name
- PICC&PAC (NCT04324346)
- Testing
- FEC75 (or EC90) x 6, FEC100 + Taxotere (EC90 + Taxotere) 3+3, Paclitaxel
- Where
- Sweden
- Volunteers
- 250 people
- Sponsor
- Swedish Red Cross University College
Breast Cancer
Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver…
- Trial name
- NRR (NCT00006110)
- Testing
- trastuzumab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 82 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Esophageal Cancer
Comparison of Nab-Paclitaxel Versus Paclitaxel in Neoadjuvant Immunochemotherapy Therapy for Esophageal Squamous Cell Carcinoma: A Retrospective IPTW-Adjusted Analysis
Taxane-based agents are widely used in the treatment of esophageal squamous cell carcinoma (ESCC). Among these, nab-paclitaxel (albumin-bound paclitaxel) and paclitaxel are the most commonly used.
- Trial name
- NCT07549269
- Testing
- The cohort included 161 patients treated with solvent-based paclitaxel and 226 treated with nanoparticle albumin-bound paclitaxel.
- Where
- 3 sites in China
- Volunteers
- 387 people
- Sponsor
- Sichuan University
Peripheral Arterial Disease
Effectiveness of Paclitaxel-coated Luminor® Balloon Catheter Versus Uncoated Balloon Catheter in the Arteria Femoralis Superficialis
The aim of this clinical trial is to evaluate the safety and efficacy of the novel Luminor® paclitaxel drug-eluting balloon (iVascular, S.L.U., Barcelona, Spain) in inhibiting restenosis and in ensuring long-term patency.
- Trial name
- EffPac (NCT02540018)
- Testing
- Transluminal Angioplasty with Paclitaxel-coated Luminor® Balloon Catheter in the Superficial Femoral and Popliteal Arteries, Transluminal Angioplasty with and non-coated (CE-marked) plain old angioplasty balloon (POBA) catheter
- Where
- 11 sites in Germany
- Volunteers
- 172 people
- Sponsor
- Jena University Hospital
Transitional Cell Carcinoma
Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer
This phase II trial studies how well paclitaxel and pembrolizumab works in treating patients with urothelial cancer that has not responded to previous treatment and has spread to other places in the body.
- Trial name
- NCT02581982
- Testing
- Laboratory Biomarker Analysis, Paclitaxel, Pembrolizumab
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Wake Forest University Health Sciences
Cancer
Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors
The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in combination with each of the following three chemotherapy regimens: Paclitaxel, 5FU plus Irinotecan (FOLFIRI), or Carboplatin plus Paclitaxel in…
- Trial name
- NCT01653470
- Testing
- Paclitaxel, 5-Fluorouracil (5FU), Carboplatin
- Where
- 5 sites in United States, Belgium and 1 more
- Volunteers
- 141 people
- Sponsor
- Bristol-Myers Squibb
Male Breast Cancer, Stage II Breast Cancer
Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer
This phase II trial is studying how well giving bevacizumab together with combination chemotherapy works in treating patients who have undergone surgery for breast cancer that has spread to the lymph nodes.
- Conditions
- Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Trial name
- NCT00119262
- Testing
- doxorubicin hydrochloride, cyclophosphamide, bevacizumab
- Where
- United States
- Volunteers
- 226 people
- Sponsor
- National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor
This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin when given together with paclitaxel in treating patients with metastatic or unresectable solid tumor.
- Trial name
- NCT00087217
- Testing
- tanespimycin, paclitaxel, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix
- Trial name
- NCT00004074
- Testing
- recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.